Insight Molecular Diagnostics Inc. — Director's Dealing 2024

Dec 26, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Oncocyte Corp (OCX)
CIK: 0001642380
Period of Report: 2024-12-26

Reporting Person: Arno Andrew (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-12-26	Common Stock, no par value	P	12500	$2.1080	Acquired	81554	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock, no par value	7804	Indirect
Common Stock, no par value	7804	Indirect

Footnotes

F1: The price of $2.1080 per share represents a weighted average of prices ranging from $2.1000 to $2.1300 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F2: These shares of Common Stock are held by JBA Investments LLC ("JBA"). The Reporting Person is the Manager of JBA and, in such capacity, has the right to vote and dispose of securities held by JBA, including the shares of Common Stock reported here.

F3: These shares of Common Stock are held by MJA Investments LLC ("MJA"). The Reporting Person is the Manager of MJA and, in such capacity, has the right to vote and dispose of securities held by MJA, including the shares of Common Stock reported here.